Q4 2025 Management View President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

A breakthrough in breast cancer research is showing promising signs in the development of a vaccine for the disease. Anixa ...

The International Agency for Research on Cancer forecasts over 35 million new cancer cases in 2050 globally. The growing ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

Diversity in clinical trials can positively impact patient care and outcomes, particularly among minority populations, Anita ...

NervGen Pharma targets a neglected market with significant unmet needs, offering high-risk, high-reward potential if NVG-291 ...

Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...

A new cancer treatment discovered by the University of California, San Diego Sanford Stem Cell Institute (SSCI) and developed ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.